Investment Rating - The report suggests focusing on innovative drugs, brain-computer interfaces, and AI medical applications, indicating a positive outlook for these sectors [1]. Core Insights - The pharmaceutical industry index decreased by 3.31% this week, underperforming the CSI 300 index by 3.39 percentage points. However, since the beginning of 2026, the pharmaceutical sector has increased by 3.14%, outperforming the CSI 300 by 1.49 percentage points [5][12]. - The current valuation level (PE-TTM) for the pharmaceutical industry is 29.40 times, with a premium of 61.10% relative to the entire A-share market [22]. - Notable sub-sectors include blood products, which had the best performance this week with a decline of only 1.0%, while the top three performing sectors since the beginning of the year are hospitals (+12.0%), offline pharmacies (+9.3%), and medical R&D outsourcing (+6.7%) [28]. Summary by Sections Investment Strategy - The report highlights a robust combination of companies including 恒瑞医药 (Hengrui Medicine), 百济神州-U (BeiGene), 美好医疗 (Meihua Medical), and others, indicating their potential for growth and investment [19]. Market Performance - The pharmaceutical industry index's performance this week was ranked 23rd, while its year-to-date performance ranked 22nd among all sectors [5][20]. - The report notes that 60 stocks in the pharmaceutical sector had positive returns this week, while 420 stocks declined [35]. Company News - 先声药业 (Xiansheng Pharmaceutical) has authorized勃林格殷格翰 (Boehringer Ingelheim) for its drug SIM0709, with an upfront payment of €42 million and a total deal value of €1.058 billion [13]. - 石药集团 (Shijiazhuang Pharmaceutical) has partnered with 阿斯利康 (AstraZeneca) for a long-acting peptide project, which includes an upfront payment of $1.2 billion and potential milestone payments totaling $3.5 billion [14]. - 同源康 (Tongyuan Pharmaceutical) has its drug TY9591 included in the priority review list, expected to be launched in 2026, targeting EGFR mutation NSCLC brain metastasis patients [15]. Financial Data - The total market capitalization of the pharmaceutical industry is approximately ¥52,861.60 billion, with a circulating market value of ¥48,153.47 billion [3]. - The industry’s TTM PE ratio stands at 37.3, compared to the CSI 300's PE ratio of 14.2, indicating a significant premium for the pharmaceutical sector [3]. Additional Insights - The report emphasizes the importance of innovative drug development and strategic partnerships in driving growth within the pharmaceutical industry, particularly in the context of emerging therapies and technologies [1][19].

Group 1 - The pharmaceutical sector has been experiencing fluctuations since September, following a strong rally, and is currently undergoing a rotation adjustment. The question arises whether the sector is worth attention after a valuation decline and if there is still growth logic [1] - The fundamentals supporting the innovative drug sector may continue to strengthen in Q4, with multiple catalysts on the horizon that could further release industrial development momentum [1] Group 2 - The policy environment for the pharmaceutical industry is improving, with the National Healthcare Security Administration and the National Health Commission jointly releasing measures to support high-quality development of innovative drugs, providing comprehensive support across five key areas [2][4] - The implementation of ICH guidelines in China is promoting more efficient and scientific drug evaluation processes, enhancing regulatory confidence [2] Group 3 - The upcoming peak season for business development (BD) transactions is expected to see increased activity, with historical data indicating that October and November are high-frequency periods for such transactions [5] - A significant deal was struck on October 8, with Innovent Biologics making a $100 million upfront payment, marking the beginning of Q4's BD activity [5] - On October 22, Innovent Biologics and Takeda Pharmaceuticals announced a global strategic collaboration worth up to $11.4 billion, setting a record for BD transaction amounts among Chinese innovative drug companies [6] Group 4 - The valuation of the pharmaceutical sector shows a significant gap from its recent five-year price peak, indicating potential for recovery [9] - The proportion of public equity funds heavily invested in the pharmaceutical sector has increased to 12.2%, suggesting that there is still room for growth compared to the historical average of 13.7% [9] - Excluding pharmaceutical-themed funds, the proportion of public equity funds in the sector is at a historical low of 6.44%, indicating potential for significant inflow of new capital if market interest increases [9] Group 5 - For ordinary investors, investing in individual innovative drug stocks poses challenges due to the need for specialized tracking capabilities across various aspects such as pipelines, clinical trials, and regulations. Therefore, considering ETFs that cover industry leaders may be a more effective strategy [10]